STTR Phase I: Implementation of a Biometric Data Software Platform to Augment Mental Health Treatment

这个小企业技术转让（STTR）项目的更广泛的影响/商业潜力是通过客观的进展报告和会后激励，从患者的第一次治疗开始，通过对患者的关怀，改善精神卫生领域的结果并降低成本。患者和临床医生都将能够通过自我报告和生理测量来跟踪和评估治疗进展。这一创新建立在强大的学术、政府和工业伙伴关系的基础上，将推动生物技术领域的研究和发展。通过展示与技术利用相关的改善成果和降低成本，这将为保险报销（使用现有CPT代码）加速市场采用铺平道路。此外，随着患者和公众对心理健康和创伤后应激障碍的教育的改善，特别是，围绕这些疾病的负面污名将减少，更多需要帮助的人将寻求帮助，而不是诉诸不健康的行为甚至自杀。这个STTR第一阶段项目提出了一种创新的方法，提供了易于解释的结果，为心理健康提供者，患者，目前的心理健康治疗和评估缺乏定性的、科学的测量方法。显然，需要一个科学的测量，因为大约8%的成年人-在这个国家的13人中有1人会在他们的一生中发展PTSD。目前，60%被诊断患有精神疾病的成年人没有接受心理健康治疗;使用经验证的科学和生理测量作为改善治疗和监测PTSD进展的基础，可以帮助减轻一些围绕精神疾病的耻辱。该项目旨在展示如何实施基于网络的平台可以通过向患者提供生理相关的反馈来改善PTSD治疗，并为临床医生提供工具来为个体患者量身定制治疗。患者将在整个治疗过程中在软件平台上可视化他们的主观测量和生理数据，并通过经验证的评估量表跟踪进展。患者在治疗中会像往常一样与他人沟通。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Technology Transfer (STTR)project is to improve outcomes and decrease costs in the mental health space by engagingpatients starting with their first therapy session through objective progress reporting andpost-session motivation. Patients and clinicians alike will be able to track and assess treatmentprogress through self-reported and physiological measures. This innovation builds upon thestrong academic, government, and industry partnerships that will advance research andinnovation in the field of biotechnology. By demonstrating improved outcomes and decreasedcosts associated with the utilization of technology, this will pave the way for insurancereimbursement (using existing CPT codes) to accelerate market adoption. Additionally, aseducation of patients and the public improves regarding mental health and PTSD in particular,the negative stigma surrounding these conditions will decrease and more people in need willseek help rather than resorting to unhealthy behavior or even suicide.This STTR Phase I project proposes to represent an innovative approach that provides easy tointerpret results tailored to mental health providers, patients, and other non-technical users.Current mental health treatment and assessment has lacked qualitative, scientifically-basedmeasurement. The need for a scientific measurement is evident, as about 8 percent of alladults - 1 of 13 people in this country will develop PTSD during their lifetime. Currently, 60%of adults diagnosed with a mental illness don't receive mental health treatment; using provenscience and physiologic measurements as the foundation for improving treatment andmonitoring progress for PTSD can help to alleviate some of the stigma surrounding mentalillnesses. This project aims to demonstrate how implementing a web-based platform canimprove PTSD treatment by providing physiologically relevant feedback to the patient and byproviding a tool for the clinician to tailor the therapy to the individual patient. Patients will havetheir subjective measures and physiological data visualized throughout treatment on a softwareplatform, with progress being tracked through validated assessment scales. Patients will becompared to others in treatment as usual. Results should yield improved quality of life anddecrease long term healthcare costs for those that use the platform.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.